 OncLive | Targeting CD20: Rituximab's Success Fuels Interest in New Agents - OncLive OncLive The first anticancer antibody on the market was rituximab, which targets the membrane protein CD20 and, since its approval in the late 1990s, it has revolutionized the treatment of B-cell malignancies, with huge improvements in survival rates. However ... |
